Literature DB >> 21602788

The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis.

Charles E Massie1, Andy Lynch, Antonio Ramos-Montoya, Joan Boren, Rory Stark, Ladan Fazli, Anne Warren, Helen Scott, Basetti Madhu, Naomi Sharma, Helene Bon, Vinny Zecchini, Donna-Michelle Smith, Gina M Denicola, Nik Mathews, Michelle Osborne, James Hadfield, Stewart Macarthur, Boris Adryan, Scott K Lyons, Kevin M Brindle, John Griffiths, Martin E Gleave, Paul S Rennie, David E Neal, Ian G Mills.   

Abstract

The androgen receptor (AR) is a key regulator of prostate growth and the principal drug target for the treatment of prostate cancer. Previous studies have mapped AR targets and identified some candidates which may contribute to cancer progression, but did not characterize AR biology in an integrated manner. In this study, we took an interdisciplinary approach, integrating detailed genomic studies with metabolomic profiling and identify an anabolic transcriptional network involving AR as the core regulator. Restricting flux through anabolic pathways is an attractive approach to deprive tumours of the building blocks needed to sustain tumour growth. Therefore, we searched for targets of the AR that may contribute to these anabolic processes and could be amenable to therapeutic intervention by virtue of differential expression in prostate tumours. This highlighted calcium/calmodulin-dependent protein kinase kinase 2, which we show is overexpressed in prostate cancer and regulates cancer cell growth via its unexpected role as a hormone-dependent modulator of anabolic metabolism. In conclusion, it is possible to progress from transcriptional studies to a promising therapeutic target by taking an unbiased interdisciplinary approach.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21602788      PMCID: PMC3155295          DOI: 10.1038/emboj.2011.158

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  71 in total

1.  A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth.

Authors:  Qianben Wang; Wei Li; X Shirley Liu; Jason S Carroll; Olli A Jänne; Erika Krasnickas Keeton; Arul M Chinnaiyan; Kenneth J Pienta; Myles Brown
Journal:  Mol Cell       Date:  2007-08-03       Impact factor: 17.970

2.  Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic.

Authors:  Andrea B Sherk; Daniel E Frigo; Christine G Schnackenberg; Jeffrey D Bray; Nicholas J Laping; Walter Trizna; Marlys Hammond; Jaclyn R Patterson; Scott K Thompson; Dmitri Kazmin; John D Norris; Donald P McDonnell
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

3.  Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis.

Authors:  K Takayama; K Kaneshiro; S Tsutsumi; K Horie-Inoue; K Ikeda; T Urano; N Ijichi; Y Ouchi; K Shirahige; H Aburatani; S Inoue
Journal:  Oncogene       Date:  2007-02-05       Impact factor: 9.867

4.  Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor.

Authors:  Biaoyang Lin; Jun Wang; Xu Hong; Xiaowei Yan; Daehee Hwang; Ji-Hoon Cho; Danielle Yi; Angelita G Utleg; Xuefeng Fang; Dustin E Schones; Keji Zhao; Gilbert S Omenn; Leroy Hood
Journal:  PLoS One       Date:  2009-08-11       Impact factor: 3.240

5.  Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells.

Authors:  K E Knudsen; K C Arden; W K Cavenee
Journal:  J Biol Chem       Date:  1998-08-07       Impact factor: 5.157

6.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

7.  A consensus DNA-binding site for the androgen receptor.

Authors:  P J Roche; S A Hoare; M G Parker
Journal:  Mol Endocrinol       Date:  1992-12

8.  In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.

Authors:  Robert Snoek; Helen Cheng; Katia Margiotti; Latif A Wafa; Charmaine A Wong; Erica Chan Wong; Ladan Fazli; Colleen C Nelson; Martin E Gleave; Paul S Rennie
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

9.  Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

Authors:  Gerhardt Attard; Alison H M Reid; Roger A'Hern; Christopher Parker; Nikhil Babu Oommen; Elizabeth Folkerd; Christina Messiou; L Rhoda Molife; Gal Maier; Emilda Thompson; David Olmos; Rajesh Sinha; Gloria Lee; Mitch Dowsett; Stan B Kaye; David Dearnaley; Thian Kheoh; Arturo Molina; Johann S de Bono
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

10.  Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity.

Authors:  Li Jia; Benjamin P Berman; Unnati Jariwala; Xiting Yan; Jon P Cogan; Allison Walters; Ting Chen; Grant Buchanan; Baruch Frenkel; Gerhard A Coetzee
Journal:  PLoS One       Date:  2008-11-10       Impact factor: 3.240

View more
  282 in total

1.  MicroRNA-224 and its target CAMKK2 synergistically influence tumor progression and patient prognosis in prostate cancer.

Authors:  Hao Fu; Hui-chan He; Zhao-dong Han; Yue-ping Wan; Hong-wei Luo; Ya-qiang Huang; Chao Cai; Yu-xiang Liang; Qi-shan Dai; Fu-neng Jiang; Wei-de Zhong
Journal:  Tumour Biol       Date:  2014-11-15

Review 2.  FOXA1: master of steroid receptor function in cancer.

Authors:  Michael A Augello; Theresa E Hickey; Karen E Knudsen
Journal:  EMBO J       Date:  2011-09-20       Impact factor: 11.598

3.  Direct cooperation between androgen receptor and E2F1 reveals a common regulation mechanism for androgen-responsive genes in prostate cells.

Authors:  D M Altintas; M S Shukla; D Goutte-Gattat; D Angelov; J P Rouault; S Dimitrov; Jacques Samarut
Journal:  Mol Endocrinol       Date:  2012-07-06

Review 4.  Calcium/calmodulin-dependent protein kinase kinase 2: roles in signaling and pathophysiology.

Authors:  Luigi Racioppi; Anthony R Means
Journal:  J Biol Chem       Date:  2012-07-09       Impact factor: 5.157

Review 5.  Metabolomic profiling of hormone-dependent cancers: a bird's eye view.

Authors:  Stacy M Lloyd; James Arnold; Arun Sreekumar
Journal:  Trends Endocrinol Metab       Date:  2015-08-01       Impact factor: 12.015

Review 6.  Evolving Lessons on the Complex Role of AMPK in Normal Physiology and Cancer.

Authors:  Biplab Dasgupta; Rishi Raj Chhipa
Journal:  Trends Pharmacol Sci       Date:  2015-12-20       Impact factor: 14.819

Review 7.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.

Authors:  Lisa M Butler; Ylenia Perone; Jonas Dehairs; Leslie E Lupien; Vincent de Laat; Ali Talebi; Massimo Loda; William B Kinlaw; Johannes V Swinnen
Journal:  Adv Drug Deliv Rev       Date:  2020-07-23       Impact factor: 15.470

8.  Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation.

Authors:  Chen-Lin Hsieh; Teng Fei; Yiwen Chen; Tiantian Li; Yanfei Gao; Xiaodong Wang; Tong Sun; Christopher J Sweeney; Gwo-Shu Mary Lee; Shaoyong Chen; Steven P Balk; Xiaole Shirley Liu; Myles Brown; Philip W Kantoff
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

9.  Lactate as a novel quantitative measure of viability in Schistosoma mansoni drug sensitivity assays.

Authors:  Stephanie Howe; Dorina Zöphel; Harini Subbaraman; Clemens Unger; Jana Held; Thomas Engleitner; Wolfgang H Hoffmann; Andrea Kreidenweiss
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

10.  Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.

Authors:  Michael A Augello; Craig J Burd; Ruth Birbe; Christopher McNair; Adam Ertel; Michael S Magee; Daniel E Frigo; Kari Wilder-Romans; Mark Shilkrut; Sumin Han; Danielle L Jernigan; Jeffry L Dean; Alessandro Fatatis; Donald P McDonnell; Tapio Visakorpi; Felix Y Feng; Karen E Knudsen
Journal:  J Clin Invest       Date:  2012-12-21       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.